Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01924260 · ClinicalTrials.gov registry record · Phase 1
Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Stage IV Pancreatic Cancer, sponsored by Edward Kim.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT01924260: Completed Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Stage IV Pancreatic Cancer, sponsored by Edward Kim.
NCT01924260 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Stage IV Pancreatic Cancer that has completed, run by Edward Kim. The registered enrollment target is 26 participants, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01924260, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Stage IV Pancreatic Cancer, has completed, sponsored by Edward Kim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and the best dose of alisertib when given together with gemcitabine hydrochloride in treating patients with solid tumors or pancreatic cancer that is metastatic or cannot be removed by surgery. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving alisertib with gemcitabine hydrochloride may be an effective treatment for solid tumors or pancreatic cancer.
Conditions Studied
Interventions
- DRUG gemcitabine
- DRUG alisertib
Study Locations (1)
California
- UC Davis Comprehensive Cancer Center - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2013-08-09 |
| Est. Completion | 2017-02-08 |
| Phase | Phase 1 |
What the finished NCT01924260 record still lists
NCT01924260 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (95% lower).
The record links to 6 conditions, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 2 interventions - of which gemcitabine is the first listed.
NCT01924260 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01924260 about?
NCT01924260 is a clinical study titled "Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer". This phase I trial studies the side effects and the best dose of alisertib when given together with gemcitabine hydrochloride in treating patients with solid tumors or pancreatic cancer that is metastatic or cannot be removed by surgery. Alisertib may stop the growth of tumor cells by blocking some ...
What is the current status of trial NCT01924260?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2013-08-09. Estimated completion is 2017-02-08.
What conditions does trial NCT01924260 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific, Stage IV Pancreatic Cancer, Stage III Pancreatic Cancer, Recurrent Pancreatic Cancer, Acinar Cell Adenocarcinoma of the Pancreas.
What interventions are being tested in trial NCT01924260?
The interventions under investigation include: gemcitabine (DRUG), alisertib (DRUG).
Who is sponsoring clinical trial NCT01924260?
This trial is sponsored by Edward Kim, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01924260 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01924260's enrollment target sits among peer trials
26 62nd of 83 higher than 21 of 83 other Unspecified Adult Solid Tumor, Protocol Specific trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Unspecified Adult Solid Tumor, Protocol Specific trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
ACTIVE NOT RECRUITING · Phase 1
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
COMPLETED · Phase 1
-
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
BMS-599626 in Treating Patients With Metastatic Solid Tumors
COMPLETED · Phase 1
-
Indole-3-Carbinol in Preventing Cancer in Healthy Participants
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI